PROTECTION AFFORDED BY WC3 ROTAVIRUS VACCINE AGAINST NATURAL (PREDOMINANTLY SEROTYPE-1) ROTAVIRUS INFECTION IN A PLACEBO-BLINDED EFFICACY TRIAL

被引：2
|
作者：
CLARK, HF
BORIAN, F
BELL, LM
MODESTO, K
FIEO, A
PLOTKIN, SA
机构：
[1] CHILDRENS HOSP,DIV INFECT DIS,PHILADELPHIA,PA 19104
[2] WISTAR INST ANAT & BIOL,PHILADELPHIA,PA 19104
来源：
PEDIATRIC RESEARCH | 1987年 / 21卷 / 04期
关键词：
D O I：
10.1203/00006450-198704010-00935
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：A323 / A323
页数：1
相关论文
共 11 条
  • [1] PROTECTIVE EFFECT OF WC3 VACCINE AGAINST ROTAVIRUS DIARRHEA IN INFANTS DURING A PREDOMINANTLY SEROTYPE-1 ROTAVIRUS SEASON
    CLARK, HF
    BORIA, FE
    BELL, LM
    MODESTO, K
    GOUVEA, V
    PLOTKIN, SA
    JOURNAL OF INFECTIOUS DISEASES, 1988, 158 (03): : 570 - 587
  • [2] IMMUNE PROTECTION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS BY A SEROTYPE-1 REASSORTANT OF BOVINE ROTAVIRUS WC3
    CLARK, HF
    BORIAN, FE
    PLOTKIN, SA
    JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (06): : 1099 - 1104
  • [3] WC3 REASSORTANT ROTAVIRUS BEARING A SEROTYPE-1 VP7 IS SAFE AND PROTECTIVE AGAINST NATURAL CHALLENGE
    CLARK, HF
    BORIAN, FE
    TUCKER, J
    LEWIS, R
    PLOTKIN, SA
    PEDIATRIC RESEARCH, 1989, 25 (04) : A175 - A175
  • [4] EFFICACY OF RHESUS ROTAVIRUS VACCINE MMU-18006 AGAINST GASTROENTERITIS DUE TO SEROTYPE-1 ROTAVIRUS
    UKAE, S
    NAKATA, S
    ADACHI, N
    KOGAWA, K
    CHIBA, S
    VACCINE, 1994, 12 (10) : 933 - 939
  • [5] EFFECT OF VACCINATION ON SEROTYPE-SPECIFIC ANTIBODY-RESPONSES IN INFANTS ADMINISTERED WC3 BOVINE ROTAVIRUS BEFORE OR AFTER A NATURAL ROTAVIRUS INFECTION
    WARD, RL
    SANDER, DS
    SCHIFF, GM
    BERNSTEIN, DI
    JOURNAL OF INFECTIOUS DISEASES, 1990, 162 (06): : 1298 - 1303
  • [6] Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial
    M. Van der Wielen
    P. Van Damme
    European Journal of Clinical Microbiology & Infectious Diseases, 2008, 27 : 495 - 501
  • [7] Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial
    Van der Wielen, M.
    Van Damme, P.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2008, 27 (07) : 495 - 501
  • [8] FIELD TRIAL OF RHESUS ROTAVIRUS OR HUMAN-RHESUS ROTAVIRUS REASSORTANT VACCINE OF VP7 SEROTYPE-3 OR SEROTYPE-1 SPECIFICITY IN INFANTS
    MADORE, HP
    CHRISTY, C
    PICHICHERO, M
    LONG, C
    PINCUS, P
    VOSEFSKY, D
    KAPIKIAN, AZ
    DOLIN, R
    JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (02): : 235 - 243
  • [9] SEROTYPE-1 REASSORTANT OF BOVINE ROTAVIRUS WC3, STRAIN WI79-9, INDUCES A POLYTYPIC ANTIBODY-RESPONSE IN INFANTS
    CLARK, HF
    BORIAN, FE
    MODESTO, K
    PLOTKIN, SA
    VACCINE, 1990, 8 (04) : 327 - 332
  • [10] Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)
    Robbin Itzler
    Gary Koch
    David O Matson
    Leif Gothefors
    Pierre Van Damme
    Mark J DiNubile
    Penny M Heaton
    BMC Pediatrics, 10
12